Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C

Authors

  • Marcus Bahra,

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Ulf Peter Neumann,

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Dietmar Jacob,

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Thomas Berg,

    1.  Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitätsklinikum Charité, Campus Virchow-Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Ruth Neuhaus,

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Jan Michael Langrehr,

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author
  • Peter Neuhaus

    1.  Klinik für Allgemein-, Viszeral-, und Transplantationschirurgie, Universitätsklinikum Charité, Campus Virchow - Klinikum, Humboldt- Universität, Berlin, Germany.
    Search for more papers by this author

Marcus Bahra MD, Chirurgische Klinik und Poliklinik, Charité, Campus Virchow-Klinikum, Humboldt Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Tel.: +49 30 450 552001; fax: +49 30 450 552900; e-mail: marcus.bahra@charite.de

Summary

Long-term outcome after liver retransplantation for recurrent hepatitis C has been reported to be inferior to other indications. The identification of factors associated which improved long-term results may help identify hepatitis C positive patients who benefit from liver retransplantation. Outcome after liver retransplantation for recurrent hepatitis C was analyzed in 18 patients (group 1) and compared with hepatitis C positive patients undergoing liver retransplantation for initial nonfunction (group 2, n = 11) and patients with liver retransplantation for other indications (group 3, n = 169). Five-year patient survival following retransplantation for groups 1, 2 and 3 was 59% 84% and 60%. Increased alanine aminotransferase (ALT) and serum bilirubin, as well as white cell count and MELD score at day of retransplantation were associated with impaired patient outcome. Five-year survival after retransplantation in patients with recurrent hepatitis C is similar to that in patients undergoing liver retransplantation for other indications. Our analysis showed MELD score, bilirubin, ALT levels and white cell counts preorthotopic liver transplantation are important predictive factors for outcome. This observational study may help select patients and identify the optimal time-point of liver retransplantation in ‘‘Hepatitis C’’ virus positive patients in the future.

Ancillary